Accelerating Global Access to Affordable Vaccines
Influenza, Malaria, Schistosomiasis, Typhoid, Cholera, Measles, adults, children and Merck KGaA, Darmstadt, Germany. What do they all have in common? Vaccines.
These diseases strike adults and children alike. Vaccines are an important part of preventing these diseases, however in many countries these diseases still run rampant. In 2016, some 10 million children did not receive vaccines, according to The World Health Organization.
The World Health Organization is encouraging countries to help overcome hurdles to vaccine use. Merck KGaA, Darmstadt, Germany is demonstrating its commitment to accelerating global access to affordable vaccines through a variety of programs.
Collaboration with Oxford University on vaccine manufacturing
Most recently, we partnered with Oxford University’s Jenner Institute, a leading research group spanning human and veterinary vaccine research and development. Using our products, systems and technologies, together we developed a cost-effective and transferable manufacturing process to accelerate vaccine development and manufacturing worldwide. The team will focus on vaccines based on adenovirus, which is critical to new vaccine development.
Since 2007, Merck KGaA, Darmstadt, Germany has been supporting the World Health Organization in the fight against schistosomiasis in Africa.
For more information on how our company collaborates with the vaccine community to solve the toughest challenges in vaccine production, visit www.emdmillipore.com/vaccines.